Article

Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation (Impact Factor: 5.61). 02/2013; 32(5). DOI: 10.1016/j.healun.2013.01.1055
Source: PubMed

ABSTRACT BACKGROUND: Pediatric patients with severe pulmonary arterial hypertension (PAH) are treated with intravenous epoprostenol or intravenous or subcutaneous treprostinil. Little is known about longitudinal hemodynamics and outcomes of epoprostenol, treprostinil, and transitions from epoprostenol to treprostinil. METHODS: This was retrospective study of 77 pediatric patients (47 idiopathic PAH, 24 congenital heart disease-PAH) receiving epoprostenol or treprostinil from 1992 to 2010 at 2 centers. Outcomes were defined as living vs dead/transplant. RESULTS: Mean age at baseline was 7.7 ± 5.2 years, with follow-up of 4.3 ± 3.4 years. Thirty-seven patients were treated with epoprostenol, 20 with treprostinil, and 20 were transitioned from epoprostenol to treprostinil. Mean pulmonary-to-systemic vascular resistance ratio (Rp/Rs) for epoprostenol was 1.0 ± 0.4, 0.8 ± 0.4, 0.8 ± 0.4, 1.0 ± 0.4, and 1.2 ± 0.4, respectively, at baseline, 1, 2, 3, and 4 years. For treprostinil, Rp/Rs was 0.9 ± 0.3, 0.7 ± 0.3, 0.5 ± 0.2, (p < 0.01 vs baseline), and 1.1 ± 0.2, respectively, at baseline, 1, 2, and 3 to 4 years, respectively. There were similar changes in mean pulmonary artery pressure and pulmonary vascular resistance index. The Rp/Rs 1 year after epoprostenol to treprostinil transition increased from 0.6 to 0.8 (n = 7). Changes not statistically significant unless noted. Eight patients died or received a transplant within 2 years of baseline; compared with the rest of the cohort, mean baseline Rp/Rs, right atrial pressure, and pulmonary vascular resistance index were significantly worse in this group. Thirty-nine patients remain on prostanoids, 17 are off, 16 died, and 5 received heart-lung transplant. Kaplan-Meier 5-year transplant-free survival was 70% (95% confidence interval, 56%-80%). CONCLUSION: There was improvement in Rp/Rs on both therapies at 1 to 2 years that was not sustained. The 5-year transplant-free survival was better than in similar adult studies.

Download full-text

Full-text

Available from: David Dunbar Ivy, Jul 04, 2015
0 Followers
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose The current REVEAL model for pulmonary arterial hypertension (PAH) uses 19 predictors to calculate a one year survival probability. There is a growing interest in the creation of simplified prediction models that use easily obtained, non-invasive and affordable predictors. We hypothesized that a simplified REVEAL model would have comparable performance to the original model. Methods and Materials REVEAL scores were calculated in 140 patients with PAH, and then recalculated excluding right heart catheterization and pulmonary function data. The original and simplified models were then used to predict one year outcomes (survival or composite survival or freedom from lung transplant (FLT)) and the performance of the models was compared. Results The c index for the original REVEAL model to predict one year survival was 0.765, and for the simplified model 0.749 (p = 0.41). For the composite outcome of survival or FLT at 1 year, the c index for the original model was 0.805 compared to 0.796 using the simplified model (p= 0.54). The observed and predicted survivals among risk strata assigned by the simplified model were not statistically different from one another (p=0.46), suggesting adequate model calibration. Conclusions A simplified REVEAL prediction model for PAH using non-invasive and routinely measured predictors had comparable performance to the original model. The benefit of such a model is increased usability, reduced cost, and identification of easily measured predictors that should be followed in routine clinical practice.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 04/2013; 32(4):S17. DOI:10.1016/j.healun.2013.01.024 · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary arterial hypertension (PAH) is a rare disease in infants and children that is associated with significant morbidity and mortality. The disease is characterized by progressive pulmonary vascular functional and structural changes resulting in increased pulmonary vascular resistance and eventual right heart failure and death. In the majority of pediatric patients, PAH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Although treatment of the underlying disease and reversal of advanced structural changes has not yet been achieved with current therapy, quality of life and survival have been improved significantly. Targeted pulmonary vasodilator therapies, including endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase type 5 inhibitors, have demonstrated hemodynamic and functional improvement in children. The management of pediatric PAH remains challenging, as treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts. This article reviews the current drug therapies and their use in the management of PAH in children.
    Paediatric Drugs 10/2013; 16(1). DOI:10.1007/s40272-013-0052-2 · 1.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Incidence data from the Netherlands has revealed an annual incidence and point prevalence of 0.7 and 4.4 for idiopathic pulmonary arterial hypertension and 2.2 and 15.6 for pulmonary arterial hypertension, respectively, associated with congenital heart disease (CHD) cases per million children. The updated Nice classification for PH has been enhanced to include a greater depth of CHD and emphasizes persistent PH of the newborn and developmental lung diseases, such as bronchopulmonary dysplasia and congenital diaphragmatic hernia. The management of pediatric PH remains challenging because treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts.
    Journal of the American College of Cardiology 12/2013; 62(25 Suppl):D117-26. DOI:10.1016/j.jacc.2013.10.028 · 15.34 Impact Factor